MAPT and Alzheimer disease: Additionally, cerebrospinal fluid (CSF) biomarkers established by the specific ratio between total levels of tau and Aβ1–42, and phosphorylated tau and Aβ1–42 has been described as a robust discriminator between FTD and AD [53,54].